# To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.

> **NCT06784921** · — · RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Breast Cancer Metastatic

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06784921
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-01
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06784921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06784921, "To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06784921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*